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Altered serine protease activity is associated with skin disorders in humans and in mice. The 
serine protease channel-activating protease-1 (CAP1; also termed protease serine s1 family 
member 8 (Prss8)) is important for epidermal homeostasis and is thus indispensable for 
postnatal survival in mice, but its roles and effectors in skin pathology are poorly defined. 
In  this  paper,  we  report  that  transgenic  expression  in  mouse  skin  of  either  CAP1/Prss8   
(K14-CAP1/Prss8)  or  protease-activated  receptor-2  (PAR2;  Grhl3PAR2/ + ),  one  candidate 
downstream  target,  causes  epidermal  hyperplasia,  ichthyosis  and  itching.  K14-CAP1/Prss8 
ectopic  expression  impairs  epidermal  barrier  function  and  causes  skin  inflammation 
characterized  by  an  increase  in  thymic  stromal  lymphopoietin  levels  and  immune  cell 
infiltrations.  strikingly,  both  gross  and  functional  K14-CAP1/Prss8-induced  phenotypes  are 
completely negated when superimposed on a PAR2-null background, establishing PAR2 as a 
pivotal mediator of pathogenesis. our data provide genetic evidence for PAR2 as a downstream 
effector of CAP1/Prss8 in a signalling cascade that may provide novel therapeutic targets for 
ichthyoses, pruritus and inflammatory skin diseases. 
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H
uman  skin  disorders  such  as  atopic  dermatitis,  psoriasis 
and ichthyoses range in severity from mild to life threat-
ening,  and  share  characteristics  of  inflammation,  defects 
in epidermal barrier function, skin desquamation and pruritus in 
affected patients (reviewed in refs 1 and 2). Our understanding   
of their molecular and genetic origins is improving3–5, with serine 
proteases emerging among possible disease-causing culprits. Gene-
targeting experiments in mice revealed a critical role for membrane-
bound serine proteases, particularly those of the S1 or trypsin-like   
family6 in postnatal epidermal barrier function7–9. It also emerged 
that inadequate regulation of serine protease activity in the skin of 
both mice7,8,10 and humans4 could disrupt skin homeostasis. How-
ever, which serine proteases need to be tightly regulated to prevent 
disease and how they mediate skin pathology when deregulated are 
still incompletely defined.
Channel-activating  protease-1  (CAP1;  also  termed  protease   
serine  S1  family  member-8  (Prss8)),  the  mouse  homologue  of 
human prostasin, is a glycosylphosphatidylinositol-anchored serine   
protease11. CAP1/Prss8 is expressed at high levels in the prostate 
gland12, and is also found in a variety of other organs such as skin, 
colon, lung and kidney13. We have previously shown that CAP1/
Prss8 is predominantly expressed in granular and spinous layers of 
the epidermis where it is crucial for epidermal barrier function and 
thereby  indispensable  for  postnatal  survival8.  Membrane-bound 
serine proteases exhibit pleiotropic functions not only by cleaving 
growth factors, zymogen proteases and extracellular matrix pro-
teins14 but also by inducing cell signalling through members of the 
proteinase-activated receptor (PAR) family of G-protein-coupled   
receptors15.  It  was  recently  demonstrated  that  CAP1/Prss8  can 
function upstream in a proteolytic cascade that culminates in PAR2 
activation16; yet, genetic evidence that CAP1/Prss8 can evoke PAR2 
signalling  in  vivo  is  lacking.  PAR2  is  widely  expressed  in  skin, 
including keratinocytes, endothelial cells and sensory nerves17–20, in 
which it has already been implicated in the regulation of keratino-
cyte proliferation and differentiation21, maintenance of the epider-
mal barrier22, inflammation17,18 and pruritus20,23. Both CAP1/Prss8 
and PAR2 are expressed in the suprabasal granular layers of the epi-
dermis8,17,24, supporting a possible interaction between the two.
In this study, to directly address the potential contribution of 
deregulated CAP1/Prss8 and PAR2 expression to skin pathology, we 
manipulated epidermal CAP1/Prss8 and PAR2 expression in trans-
genic mouse lines (K14-CAP1/Prss8, Grhl3PAR2/ + ). The two models 
yielded modestly increased as well as ectopic expression of CAP1/
Prss8 or PAR2, and exhibited similar phenotypes characterized by 
scaly skin, hyperplastic epidermis and scratching behaviour. Having 
established the ability of protease and signalling receptor to inde-
pendently cause skin pathology, we addressed whether they also 
cooperated to drive pathogenesis as might be suggested by signal-
ling studies16. We indeed observed that the K14-CAP1/Prss8 trans-
gene completely lost its capacity to induce skin pathology in the 
absence of PAR2, placing PAR2 as a pivotal mediator downstream 
of CAP1/Prss8 in this model. We thus demonstrate that altered 
CAP1/Prss8  expression  triggers  PAR2-dependent  inflammation, 
ichthyosis and itching, supporting the requirement for tight control 
of protease activity in skin homeostasis, and implicating PAR2 as a 
potential mediator of pathologies linked to loss of serine protease 
regulation in skin.
Results
Generation  and  characterization  of  K14-CAP1/Prss8  mice. 
To  study  the  biological  consequence  of  deregulated  CAP1/Prss8 
expression in skin, we generated transgenic mice expressing the 
full-length mouse CAP1/Prss8 coding sequence13 under the control 
of the human keratin-14 promoter25 (Fig. 1a). This promoter targets 
gene expression to keratinocytes of the basal layer of the epidermis 
and the outer root sheath of hair follicles25. Pronuclear injections of 
the K14-CAP1/Prss8 transgene construct yielded five founders, two 
of which were fertile and transmitted the transgene to produce two 
independent stable transgenic lines (termed lines 1 and 2; Fig. 1b,c). 
The transgene was transmitted according to Mendelian inheritance 
in both lines (line 1: 54% tg, n = 95; line 2: 54% tg, n = 72), suggesting 
that the level of CAP1/Prss8 expression obtained did not interfere 
with embryonic development. For line 1, only male mice (all of them) 
were transgenic, indicating integration of the transgene into the Y 
chromosome. Both transgenic lines expressed the transgene in skin 
as determined by immunohistochemistry (Fig. 1d; Supplementary 
Fig.  S1a).  Analysis  of  total  (transgene-driven  plus  endogenous) 
expression of CAP1/Prss8 demonstrated a 1.1- and 4.7-fold increase 
in transcript levels and a 1.1- and 2.9-fold increase in protein levels 
in lines 1 and 2, respectively (Fig. 1e,f), indicating higher CAP1/
Prss8 expression levels in line 2.
Epidermal  defects  and  death  in  K14-CAP1/Prss8  mice.  K14-
CAP1/Prss8  transgenic  mice  were  easily  discernible  from  their   
control littermates just a few days after birth by their scaly skin 
(ichthyosis),  which  progressed  with  age  and  was  evident  most 
prominently in the ventral-abdominal region and the tail (line 2, 
Fig. 2a, line 1; Supplementary Fig. S1b). Both transgenic lines mani-
fested ichthyosis with 100% penetrance, as well as abnormal hair 
growth (hypotrichosis) relative to littermate controls (Fig. 2b). No 
histopathological  abnormalities  were  observed  in  other  organs, 
such as thymus, tongue, oesophagus, heart, liver, lung and spleen 
(Supplementary Fig. S2). Histological analysis revealed epidermal 
hyperplasia (acanthosis) in transgenic mice from as early as 2 days 
of age (Fig. 2c; Supplementary Fig. S1c) associated with enhanced 
proliferation of keratinocytes, as evidenced by a threefold increase 
in the number of Ki67-positive cells in the stratum basale (Fig. 2d), 
without an accompanying change in the number of apoptotic cells 
in the epidermis (Fig. 2e). In addition to epidermal hyperplasia, the 
dermis of K14-CAP1/Prss8 transgenic mice was more cellular with   
a notable increase in the number of haematoxylin-stained nuclei 
(Fig. 2c).
Despite differences in CAP1/Prss8 expression levels, mice from 
both  transgenic  lines  also  manifested  a  significant  reduction  in 
body weight (Fig. 2f; Supplementary Fig. S1d) accompanied by an 
up to twofold increase in transepidermal water loss (TEWL) evi-
dent in 2-week-old animals (Fig. 2g; Supplementary Fig. S1e) and 
maintained in adults (TEWL: 3.31 g m − 2 h − 1 in wild type (wt) ver-
sus 6.90 g m − 2 h − 1 in tg, P < 0.05, n = 6 and 7, respectively, in line 1. 
2.87 g m − 2 h − 1 in wt versus 6.02 g m − 2 h − 1 in tg, P < 0.05, n = 6 and 
4, respectively, in line 2; Body weight: 37.49 g in wt versus 32.62 g 
in tg, n = 6 and 7, respectively, in line 1 and 37.64 g in wt versus 
26.06 g in tg, P < 0.001, n = 6 and 4, respectively, in line 2) indica-
tive of a defect in the skin barrier function. Many transgenic mice   
from line 2 died within the first 2 weeks (~55 versus 10% in line 1,   
Fig.  2h;  Supplementary  Fig.  S1f),  but  survival  was  not  further 
impaired thereafter. Although we did not address it directly, we 
speculate  that  death  of  these  animals  may  be  a  consequence  of 
severe dehydration.
Altered lipid and protein content in K14-CAP1/Prss8 mice. To 
explore the basis for skin barrier defects observed in K14-CAP1/
Prss8 transgenic mice, we first looked for alterations in expression 
of keratinocyte differentiation markers by immunohistochemistry 
and western blot. Expression of keratin-1, loricrin, filaggrin and 
involucrin appeared to be more widespread within the epidermis 
of K14-CAP1/Prss8 mice, but there was no obvious change in distri-
bution  within  the  differentiated  layers  (Fig.  3a;  Supplementary   
Fig. S1g), and expression levels were normal with the exception 
of filaggrin. Levels of all proteolytically cleaved intermediates of   
filaggrin were increased (Fig. 3b,c; Supplementary Fig. S1h,i). More-
over,  the  differentiation  marker  keratin-14,  normally  expressed ARTICLE     
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exclusively in the stratum basale and hair follicles, was now detected 
in all nucleated epidermal cell layers. The expression of keratin-6, 
normally present only in hair follicles, was also detectable in inter-
follicular keratinocytes (Fig. 3a; Supplementary Fig. S1g), consistent 
with epidermal hyperplasia.
To test the integrity of intercellular tight junctions in the granu-
lar layer of the epidermis, we injected NHS-LC-biotin (600 Da) into 
the dermis and subsequently visualized its diffusion on sections 
stained with fluorescently conjugated streptavidin. NHS-LC biotin 
diffused freely between cells up to the second-last nucleated layer 
of the epidermis with no discernable difference between transgenic 
mice and littermate controls (Fig. 3a). Thus, the epithelial barrier   
within  the  granular  layer  appeared  fully  functional  at  least  for   
molecules ≥600 Da.
The extracellular lipid barrier in the stratum corneum consists 
mainly of ceramides, free fatty acids and cholesterol present in a 
unique and stoichiometric composition. The ceramides are prefer-
entially composed of probarrier lipids glucosylceramide, sphingo-
myelin and cholesterol sulphate26. Ceramide levels were significantly 
higher in transgenic mice (Fig. 3d; Supplementary Fig. S1j), and 
more ceramide forms with longer fatty acids were present as seen 
by ceramide fractionation and densitometric quantification (Cer(C-
26)-NS, Cer(C26-AS), Cer(C26-NH) and Cer(EOS); Supplementary 
Table S1), as well as more ceramide precursors glucosylceramide 
and sphingomyelin. Cholesterol sulphate levels were nearly 1.8-fold   
higher  than  that  of  controls  (Fig.  3e;  Supplementary  Fig.  S1k). 
Covalently bound lipids, which are also important for skin barrier   
function27,  were  then  separated  into  ω-hydroxylated  fatty  acid   
and Cer(OS), showing that Cer(OS) levels were only 6.3% of that   
of control mice in line 2 (Fig. 3f) and 14% of that of control mice in 
line 1 (Supplementary Fig. S1l).
The hydrophobic water-protective barrier of the skin consisting 
of lipids originates from lamellar bodies secreted by keratinocytes 
of the granular layer28. Electron microscopy analyses revealed that 
secretion of lamellar bodies is diminished in the transgenic epider-
mis and that numerous lamellar body-like inclusions are present 
in  transgenic  corneocytes  (Fig.  3g).  The  stratum  granulosum– 
stratum corneum interface appeared to be widened in transgenic 
mice, containing less vesicular lamellar bodies and more electron-
dense  amorphous  material.  The  process  of  corneodesmosome   
degradation and stratum corneum desquamation was delayed in   
the  transgenic  epidermis  relative  to  control  epidermis  (Fig.  3g). 
Thus,  defective  epidermal  barrier  function  in  K14-CAP1/Prss8 
transgenic mice is likely to originate from altered epidermal protein- 
lipid composition.
Itching and inflamed skin in K14-CAP1/Prss8 mice. Transgenic 
animals surviving till adulthood frequently exhibited skin lesions 
(Fig. 4a; Supplementary Fig. S1m) possibly caused or aggravated by 
increased scratching behaviour (Fig. 4b; Supplementary Fig. S1n), 
which was evident after weaning and persistent throughout life. 
Lesions were sometimes accompanied by inflammation and swell-
ing of regional lymph nodes, which were found to be enriched in 
plasma cells (Fig. 4a; Supplementary Fig. S1m).
Epidermal thickening and increased dermal cellularity (Fig. 2c) 
are often observed in mice with skin inflammation29. To address   
the characteristics and the origin of the inflammatory phenotype and 
how it correlated with epidermal hyperplasia, barrier dysfunction 
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Figure 1 | Generation of K14-CAP1/Prss8 transgenic mice. (a) scheme of the K14-CAP1/Prss8 construct containing the mouse CAP1/Prss8 coding 
sequence (cDnA, g.i. 19111159), the human K14 promoter, the rabbit β-globin intron and the human growth hormone polyadenylation signal (polyA). 
Restriction sites used for isolation of the transgene (ClaI, NotI) and for southern blot analysis (EcoRV) are indicated. For transgene-specific genotyping, 
primers 1 and 2, and for reverse transcriptase (RT)-PCR, primers 3 and 4 (arrows), were used. (b) Detection of K14-CAP1/Prss8 transgenic mice (line 1 and 
line 2) following southern blot analysis (wild type, wt, 12 kb; transgenic, tg, 3.6 kb). (c) PCR genotyping using transgene-specific primers 1 and 2 (see a) 
and myogenin-specific primers (myo; endogenous control). (d) Immunofluorescence (green) shows transgenic CAP1/Prss8 expression in the basal layer 
of the epidermis in K14-CAP1/Prss8 transgenic mice. The white dotted line represents the basal membrane. nuclei were counterstained with DAPI (blue). 
The white bar indicates 20 µm; (b–d) n≥4 mice/genotype. (e) CAP1/Prss8 gene expression in the skin was determined  by quantitative RT–PCR analysis 
and normalized to β-actin. Line 1: n = 3 animals/genotype. Line 2: wt, n = 2 (data: 0.92 and 0.87) and tg, n = 4 animals analysed. (f) CAP1/Prss8 protein 
expression was quantified by western blotting and loading was controlled by β-actin. Line 1: n = 3 animals per genotype. Line 2: n = 4 animals per genotype. 
All data are presented as mean ± s.e.m.ARTICLE
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and itching, we explored the expression of cytokines and procy-
tokines in the skin of K14-CAP1/Prss8 transgenic mice. Interleukin-
1α (IL-1α), interleukin 1β (IL-1β), thymic stromal lymphopoietin 
(TSLP) and the extracellular matrix remodelling enzyme matrix 
metalloproteinase-9  (MMP9)  were  upregulated  relative  to  litter-
mate controls (Fig. 4c). Histological staining of 2-week-old trans-
genic skin showed no evidence of parasites, blood cells (Giemsa 
staining), lymphocytes or mucopolysaccarides, and hence no fungal 
infections (periodic acid-Schiff). However, S100, a common antigen 
for dendritic cells and macrophages, and the macrophage-specific 
antigen F4/80 (ref. 30) were both more abundant in the skin of K14-
CAP1/Prss8 transgenic mice than in that of littermate controls. Con-
sistent with the increase in antigen-presenting cells, CD3-positive T 
cells were also more abundant in the skin of K14-CAP1/Prss8 trans-
genic mice (Fig. 4d,e). Fluorescence-activated cell sorting (FACS) 
analyses of 6-day-old pups revealed an increase in the number of 
CD11c- (a marker for dendritic cells31), F4/80- and CD3-positive 
cells, and showed abnormal presence of CD3-positive/Vg3-nega-
tive T cells32 in the K14-CAP1/Prss8 transgenic skin already at this 
time (Fig. 4f). Two-day-old K14-CAP1/Prss8 transgenic pups also 
had increased numbers of S100-positive cells (Fig. 4g,h), but there 
was not yet a difference in F4/80 staining at this time (Fig. 4g). This 
suggests an inflammatory phenotype in the skin of transgenic mice 
with very early onset, and a potential initiating role for dendritic 
cells in this process.
As dendritic cell-mediated skin inflammation has been linked to 
TSLP production by keratinocytes33, we further investigated TSLP 
expression in the skin by real-time PCR. Although no difference 
was seen at embryonic day 17.5 (E17.5) or at postnatal day 1 (P1), 
a dramatic increase in TSLP expression was observed in transgenic 
skin at P2, P7 and P14 (Fig. 4i). No difference in TEWL or body 
weight was observed at P1, P2 and P5 (Fig. 4j,k), indicating that 
the defective barrier function and decrease in body weight might 
be secondary to epidermal hyperplasia and skin inflammation. Pri-
mary keratinocytes derived from transgenic and control littermates 
at P2 showed increased TSLP expression (Fig. 4l) and prolifera-
tion rates (Fig. 4m), suggesting that hyperplasia and inflammation 
might both originate in the transgenic keratinocytes. Transcripts for 
proinflammatory mediators IL-1α, IL-1β and MMP9 were barely 
or not at all detectable in the same cells (Fig. 4l). Thus, chronic skin 
inflammation, characterized by immune cell infiltration and expres-
sion of procytokines and cytokines, occurs early in parallel to epi-
dermal hyperplasia in K14-CAP1/Prss8 transgenic mice. Although 
apparently not causative, barrier dysfunction and itching may later 
aggravate these phenotypes.
Ichthyosis and itching in Grhl3PAR2/ +  mice. To probe the contri-
bution of PAR2 signalling to skin disease, we addressed whether 
increased expression of PAR2 in mouse skin might induce a patho-
logical transformation similar to what had been observed with altered 
CAP1/Prss8 activity. We inserted a cassette consisting of the mouse 
PAR2 coding sequence followed by an internal ribosomal entry site 
and the lacZ reporter gene at the start codon of the grainyhead-like-3   
(Grhl3) gene (Grhl3PAR2/ + ) by homologous recombination (Fig. 5a,b).   
The  Grhl3  locus  drives  the  expression  of  PAR2  throughout  the 
epithelial ectoderm from mid-gestation onwards16,34,35. Consistent 
with simultaneous interruption of the Grhl3 gene, mice with PAR2 
inserted in both alleles (Grhl3PAR2/PAR2) died perinatally with spina 
bifida34. Therefore, Grhl3PAR2/ +  mice were used throughout this study 
for transgenic PAR2 overexpression. Importantly, mice carrying one 
functional allele of the Grhl3 gene (Grhl3 + / − ) do not exhibit phe-
notypic differences compared to wt controls34, and knock-in of the 
Cre recombinase into the Grhl3 gene locus also affects Grhl3 gene 
expression, but does not trigger skin pathology16.
The expression of the Grhl3PAR2/ +  allele, as monitored by lacZ 
staining, was found predominantly in the suprabasal layers of the 
epidermis (Fig. 5c). Although Grhl3PAR2/ +  mice appeared normal at 
birth, they started to exhibit a scaly skin, mostly evident on the tail, 
and epidermal hyperplasia from 2 weeks onwards (Fig. 5d). Similar 
to K14-CAP1/Prss8 transgenic mice, Grhl3PAR2/ +  animals displayed 
increased scratching behaviour in adulthood (Fig. 5e) and severe 
skin lesions associated with occasional lymph node swelling (Fig. 5f).   
Notably, scratching behaviour was not observed in young mice or   
in adult mice without lesions, and did not appear to precede lesion 
formation. The common features in the phenotype of Grhl3PAR2/ +  
and K14-CAP1/Prss8 transgenic mice support a possible role for 
PAR2 in CAP1/Prss8-induced skin pathology.
PAR2 deficiency rescues K14-CAP1/Prss8-induced skin defects. 
To  address  whether  CAP1/Prss8  can  trigger  PAR2  activation   
in vivo and to experimentally test whether the similarities between 
Grhl3PAR2/ +  and K14-CAP1/Prss8 transgenic animals were due to 
excessive PAR2 activation in both models, we crossed K14-CAP1/
Prss8 transgenic mice from line 2 with mice constitutively and glo-
bally deficient in PAR2 (PAR2 − / − ) that do not exhibit obvious skin 
abnormalities36. Mice carrying the K14-CAP1/Prss8 transgene that 
were either wt (K14-CAP1/Prss8) or heterozygous mutant for PAR2 
(K14-CAP1/Prss8:PAR2 + / − )  displayed  scaly  skin  with  epidermal 
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Figure 2 | Phenotype of K14-CAP1/Prss8 transgenic mice.  
(a) macroscopic appearance of transgenic mice and littermate  
controls at 1 week (1 wk), 2 weeks (2 wk) and 5 months (5 mo) of age.  
(b) Quantification of the number (nb.) of hair follicles in transgenic versus 
control skin. n = 3 mice per genotype, *P < 0.05. (c) Haematoxylin and eosin 
analyses of 2-day (2 d)-, 2-week (14 d)- and 5-month (5 mo)-old K14-
CAP1/Prss8 mice compared with wild-type littermates. White bars indicate 
the thickness of the epidermis. scale bars indicate 20 µm. n = 3 mice per 
genotype. (d) Quantification of the number of Ki67-positive cells in the 
epidermis of 2-week-old animals. (e) Quantification of the number (nb.) of 
cells undergoing apoptosis in the epidermis of K14-CAP1/Prss8 versus wild-
type littermates (n = 3 mice per genotype, ns: not significant). (f) Body 
weight measurements of 2-week-old male (m) and female (F) transgenic 
mice and littermate controls, *P < 0.05. (g) Transepidermal water loss 
(TEWL) measurements of male and female transgenic mice. n≥4 animals 
per group, **P < 0.01. (h) survival curves of K14-CAP1/Prss8 versus  
wild-type littermates. All data are presented as mean ± s.e.m.ARTICLE     
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hyperplasia (Fig. 6a). In contrast, no scaling, epidermal hyperplasia 
or premature lethality was observed in K14-CAP1/Prss8 transgenic 
mice that were homozygous mutant for PAR2 (K14-CAP1/Prss8:
PAR2 − / − , Fig. 6a and Table 1). Despite the absence of PAR2, these 
mice still expressed the K14-CAP1/Prss8 transgene (Fig. 6a,b). The 
rescue was also evident functionally, as K14-CAP1/Prss8:PAR2 − / −  
mice exhibited TEWL in the same range as that of wt controls but 
significantly different from that of K14-CAP1/Prss8:PAR2 + / +  litter-
mates (Fig. 6c). Moreover, whereas K14-CAP1/Prss8 mice displayed 
a significantly lower body weight compared with controls, the K14-
CAP1/Prss8:PAR2 − / −  mice were indistinguishable from littermate 
controls in this regard (Fig. 6d). Surprisingly, heterozygosity for 
PAR2 was sufficient to reverse the increased water loss and reduced 
body weight observed in K14-CAP1/Prss8 transgenic mice, despite 
persistence of ichthyotic and hyperplastic phenotypes (Fig. 6c,d).   
Moreover, expression levels of inflammatory markers IL-1α, IL-1β,   
TSLP  and  MMP9,  as  well  as  of  macrophage  and  dendritic  cell   
markers  anti-F4/80  and  anti-S100,  were  indistinguishable  from   
control levels in K14-CAP1/Prss8:PAR2 − / −  animals (Figs 4c and 6e,f).   
K14-CAP1/Prss8:PAR2 + / −  mice manifested an intermediate pheno-
type, suggesting a dose-dependent effect of PAR2. Thus, absence of 
PAR2 completely rescued hyperplasia, barrier dysfunction, inflam-
mation and ichthyosis caused by altered CAP1/Prss8 expression 
in the skin, establishing PAR2 as a pivotal mediator of K14-CAP1/
Prss8-driven skin pathology in this model.
Expression of CAP1/Prss8 and PAR2 in human skin. CAP1/Prss8 
immunodetection on skin cross-sections from four healthy con-
trols and from five acute, two atopic and three chronic dermatitis 
patients showed defined localization of CAP1/Prss8 in the granu-
lar layer of the human epidermis (Fig. 7) similar to CAP1/Prss8 
expression in murine skin8. In healthy controls and acute dermatitis 
patients, CAP1/Prss8 was localized both intracellularly and at the 
plasma membrane. In patients with chronic and atopic dermatitis, 
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CAP1/Prss8 appeared to be predominantly expressed at the plasma 
membrane. PAR2 expression was seen in suprabasal keratinocytes 
in the same samples and appeared to be more extensive in chronic 
and atopic dermatitis patients, following hyperplasia. It is thus con-
ceivable that differential expression of CAP1/Prss8 and/or PAR2 in 
diseased versus healthy skin may contribute to the pathogenesis of 
these disorders.
Discussion
Altered  activity  of  serine  proteases4,7,8,10,37  and  serine  protease 
inhibitors5,9,38 can severely compromise skin homeostasis in mice 
and humans. In this study we used mouse models to demonstrate 
that increased expression of either the membrane-tethered serine 
protease CAP1/Prss8, or PAR2, a candidate downstream effector,   
is sufficient to induce skin disease in mice and that CAP1/Prss8-
elicited pathogenesis is fully dependent on PAR2.
Transgenic  K14-CAP1/Prss8  mice  exhibited  severe  ichthyosis, 
hyperplasia, epidermal barrier defects and inflammation. Intrigu-
ingly, lack of one PAR2 allele associated with CAP1/Prss8 over-
expression was sufficient to completely reverse the increased TEWL 
and body weight loss, but not ichthyosis and hyperplasia, suggest-
ing that barrier dysfunction was not secondary to epidermal hyper-
plasia.  Increased  proliferation  and  TSLP  production  in  primary   
keratinocytes isolated from K14-CAP1/Prss8 transgenic mice sug-
gested that hyperplasia and inflammation were both, at least in part, 
directly triggered by a protease signalling cascade in keratinocytes, 
supporting  a  cell-autonomous  phenotype.  TSLP  production  by 
epithelial cells has been shown to trigger dendritic cell-mediated 
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inflammation33, and it is well established that dendritic cells migrate 
from  inflamed  peripheral  tissues  to  the  closest  draining  lymph   
node to orchestrate adaptive immune responses39. PAR2 signalling 
was recently shown to promote dendritic cell trafficking to lymph 
nodes and subsequent T-cell activation40. In our K14-CAP1/Prss8 
model, CD11c- and S100-positive dendritic cells were found to be 
more abundant in the skin, supporting a potential role for TSLP 
expression  in  immune  cell  recruitment  and  activation.  Consist-
ent with these findings, CAP1/Prss8 transgenic skin exhibited an 
increase in CD3-positive T cells, as demonstrated by both immuno-
histochemistry and FACS quantification. Taken together, these data 
suggest a possible CAP1/Prss8-PAR2-TSLP cascade in which TSLP, 
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mobilized  by  CAP1/Prss8-elicited  PAR2  activation  on  keratino-
cytes, stimulates dendritic cells that then recruit T cells to start an 
adaptive inflammatory response.
Increased  scratching  behaviour  was  documented  in  both   
Grhl3PAR2/ +  knock-in and K14-CAP1/Prss8 transgenic mice. Itching 
sensation can be induced by dry, damaged and inflamed skin, and 
numerous epithelial and immune mediators can activate and sensi-
tize sensory nerve endings and even modulate their growth (reviewed 
in ref. 41). However, there is also a body of evidence to suggest that 
PAR2 can function as a direct mediator of pruritus in humans20 
and mice23. Functional PAR2 is present on primary spinal affer-
ents42, and proteases might activate PAR2 on sensory nerves in the   
skin. Importantly, however, we aimed to drive PAR2 expression in 
epithelial cells, not in sensory nerves, and, as predicted from the 
expression pattern of Grhl3 (ref. 35), dorsal root ganglia or peri-
pheral nerves are not targeted. Thus, although itching might increase 
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Table 1 | PAR2 deficiency prevents the K14-CAP1/Prss8-induced phenotype in double-transgenic K14-CAP1/Prss8:PAR2 − / −  mice 
(line 2).
Genotype K14-CAP1/Prss8 PAR − / −  K14-CAP1/Prss8 PAR2 + / −  K14-CAP1/Prss8 PAR2 + / + 
Breeding pairs PAR − / −  PAR + / −  PAR2 + / + 
K14-CAP1/Prss8 PAR2 + / −  
×PAR2 + / − , n=135
18 20 34 31 16 16
Observed, % 13.3 14.8 25.2 23.0 11.9 11.9
Expected, % 12.5 12.5 25 25 12.5 12.5
K14-CAP1/Prss8 PAR2 + / −  
×PAR2 − / − , n=71
12 16 26 17  −   − 
Observed, % 17 23 37 24  −   − 
Expected, % 25 25 25 25  −   − 
CAP1/Prss8 scaly skin phenotype  −   −   +   −   +   − 
Animals found dead 0 0 0 0 6 0
Pups were analysed during the first 3 weeks after birth. number of mice for the recorded genotypes is indicated.ARTICLE     
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lesion severity in older animals, and although neuronal PAR2 could 
be involved in itching sensation by paracrine activation of neuronal 
PAR2 in the CAP1/Prss8 model, itching did not appear to provoke 
the K14-CAP1/Prss8 and Grhl3PAR2/ +  phenotypes.
Exploring a potential role for CAP1/Prss8 as an activator of PARs 
during neural tube closure, it was recently observed that CAP1/
Prss8 was able to trigger PAR2-dependent signalling in a kerati-
nocyte cell line. However, CAP1/Prss8 could not directly activate 
PAR2; it instead turned out that CAP1/Prss8-induced signalling 
in the systems studied was dependent on intermediate activation 
of the serine protease pro-CAP3/matriptase, which in turn was a 
remarkably potent and specific activator of PAR216. Constitutive 
CAP3/matriptase  and  skin-specific  CAP1/Prss8  knockout  mice 
exhibit similar phenotypes7,8,43 and CAP1/Prss8 was found exclu-
sively in its inactive form in CAP3/matriptase/MT-SP1-deficient 
skin,  demonstrating  that  CAP3/matriptase  also  activates  CAP1/
Prss8 in mouse skin. Hence, these findings strongly point to a more 
complex serine protease cascade, in which other components, such 
as additional serine proteases and serine protease inhibitors, could 
be involved. CAP3/matriptase has been found to be mutated in 
human autosomal recessive ichthyosis with hypotrichosis and ich-
thyosis in mice resulting from loss of function of HAI-1, a CAP3/
matriptase inhibitor9,44, can be rescued with low CAP3/matriptase 
activity9.  This  indicates  that  excessive  CAP3/matriptase  activity 
can indeed lead to skin disease, and enhanced CAP1/Prss8 expres-
sion could well contribute to the phenotype. Whereas ablation of   
PAR2 from LEKTI-null animals inhibited prenatal production of 
TSLP,  but  not  cutaneous  inflammation  in  adulthood45,  ablation   
of CAP3/matriptase from LEKTI-deficient mice substantially amel-
iorated the phenotype of this mouse model of Netherton syndrome46. 
Thus, CAP3/matriptase clearly has effectors other than PAR2. Fur-
thermore, the phenotype of K14-CAP1/Prss8 transgenic mice dif-
fers from the K5-driven CAP3/matriptase overexpressing model10.   
Itching and severe skin lesions independent of tumour formations 
were not reported in K5-CAP3/matriptase transgenic mice10, and 
we never observed spontaneous tumour formation in CAP1/Prss8 
transgenic animals, even when histopathologically followed up until 
their death. Finally, CAP1/Prss8 has been reported to have biologi-
cal activity independent of its catalytic triad47,48; hence, we cannot 
exclude that CAP1/Prss8 elicits a protease cascade leading to PAR2 
signalling by a cleavage-independent mechanism.
Besides functioning upstream of PAR2, as demonstrated here, 
CAP1/Prss8 is known to be involved in the activation of the highly 
amiloride-sensitive  epithelial  sodium  channel  ENaC49.  Complete 
ENaC  knockout  mice  die  postnatally  because  of  impaired  lung 
fluid clearance50 and exhibit dehydration similar to skin-specific 
CAP1/Prss8-deficient  animals8,51.  Other  epidermal  effectors  of 
CAP1/Prss8 are filaggrin and occludin, both of which are processed 
normally in ENaC-deficient skin8,51. We therefore consider a contri-
bution of ENaC to the K14-CAP1/Prss8-mediated skin phenotype 
as unlikely.
PAR2 has been implicated in inflammatory dermatosis17,52 and 
two natural mutations of CAP1/Prss8 have been found as causa-
tive of skin defects in rodents53. In human epidermis we found that 
CAP1/Prss8  expression,  mainly  in  the  granular  layer,  appeared 
more concentrated to the plasma membrane in affected skin from 
patients with atopic and chronic dermatitis relative to skin from 
healthy controls, and was accompanied by enhanced PAR2 expres-
sion in the epidermis of the same affected subjects. Observations 
in our transgenic models should prompt further investigation into 
whether  CAP1/Prss8,  its  inhibitors,  PAR2  and  its  other  activa-
tors are deregulated in diseased human skin. K14-CAP1/Prss8 and   
Grhl3PAR2/ +  mice may also serve as models to test the efficacy of   
protease  inhibitors  and/or  PAR2  antagonists  against  ichthyosis,   
pruritus and inflammatory skin disorders.
Methods
Mice and primary cell culture. K14-CAP1/Prss8 transgenic mice were gener-
ated by cloning mouse CAP1/Prss8 cDNA (Genbank g.i. 19111159) into the 
pBHR2(SmaI) vector25,54 (See Supplementary Methods). The linearized vector 
was microinjected into B6D2F1 hybrid zygotes. Transgenic lines were maintained 
in the hemizygous state. Transgenic mice were genotyped by PCR and Southern 
blot analysis of genomic DNA extracted from tail biopsies55. Grhl3PAR2/ +  knock-in 
mice were generated by targeting 129X1/SvJ-derived E14 ES cells using standard 
techniques, essentially as described for Grhl3Cre/ +  mice16, except that Cre cDNA was 
replaced by mouse PAR2 cDNA. Further details of cloning are provided in Supple-
mentary Information. The Grhl3PAR2/ +  phenotype was observed in both C57BL6/J-
129X1/SvJ mixed and FVB/n strain backgrounds. Mice from both strains were 
used for the experiments. Experimental procedures and animal maintenance 
followed federal guidelines and were approved by local authorities.
Mouse epidermal keratinocytes were isolated from pups and cultured in vitro56. 
Cell proliferation was quantified using the Quick Cell Proliferation Testing Solu-
tion (GenScript) according to instructions provided by the manufacturer.
Measurement of scratching behaviour. For K14-CAP1/Prss8 mice and littermate 
controls, simultaneous experiments on three mice in three individual cages were 
conducted in the absence of investigators. Mice could not see each other during 
the experiment. The mice were videotaped for 15–20 min for later quantification of 
scratching behaviour. One scratch was considered as lifting of a limb towards the 
body with subsequent replacement of the limb on the bedding. For Grhl3PAR2/ +  mice 
and littermate controls, mouse behaviour was recorded in the absence of investiga-
tors and the time spent grooming and/or scratching quantified in a 5 min time 
period and expressed as percentage of total time.
Immunofluorescence and histology. For paraffin-embedded sections: Slides 
were incubated with primary antibodies for 1 h at room temperature following 
rinsing with PBS. Antigen retrieval was performed for 10 min in TEG buffer. 
Slides were washed in 50 mM NH4Cl in PBS for 30 min and blocked by 1% BSA, 
0.2% gelatine, 0.05% Saponin in PBS at room temperature for 10 min, three times. 
Primary antibody was diluted in 0.1% BSA, 0.3% Triton X-100 in PBS, overnight 
at 4 °C. Antibodies against keratin-14, keratin-1, keratin-6, involucrin, loricrin and 
filaggrin were purchased from Covance and diluted 1:1,000 or 1:4,000 (keratin-14). 
Affinity-purified CAP1/Prss8 rabbit anti-mouse antiserum57 was diluted 1:200. 
Rabbit polyclonal antibody PAR2 (H-99; sc-5597) was provided by Santa Cruz 
Biotechnology and diluted 1:1,000. Slides were rinsed three times for 10 min in 
PBS containing 0.1% BSA, 0.2% gelatine and 0.05% saponin at room temperature 
and the secondary antibody (Alexa Fluor 488, diluted 1:5,000) was diluted in 0.1% 
BSA, 0.3% Triton X-100 in PBS. Nuclei were counterstained with 4,6-diamidino-2-
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Figure 7 | Localization of CAP1/Prss8 and PAR2 in human epidermis. 
Immunohistochemistry of CAP1/Prss8 and PAR2, both in green, in human 
skin sections. nuclei are counterstained with DAPI (blue). Bottom panel: 
parallel sections in which primary antibodies were omitted (negative 
control; no 1 Ab). The pictures are representative of biopsies analysed 
from two adult subjects with atopic dermatitis, five with acute dermatitis, 
three with chronic dermatitis and from four healthy controls. Dashed white  
lines represent epidermal/dermal junction. scale bars represent 10 µm.  
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phenylindole (DAPI) 0.2 µg ml − 1 in mounting media (Dako Schweiz AG). Staining 
was visualized using an LSM confocal microscope (LSM 510 Meta, Carl Zeiss 
MicroImaging Inc.). For cryosections: Tissue-Tek O.C.T.-embedded skin was fixed 
in 2% paraformaldehyde (PFA) in PBS and permeabilized with 0.1% SDS in PBS. paraformaldehyde (PFA) in PBS and permeabilized with 0.1% SDS in PBS. PFA) in PBS and permeabilized with 0.1% SDS in PBS. 
After blocking with 2% BSA and 3% normal goat serum (NGS), sections were incu- normal goat serum (NGS), sections were incu- NGS), sections were incu-
bated with a fluorescein isothiocyanate-conjugated rat anti-mouse CD3 antibody 
(555274, BD Pharmingen, diluted 1:100) for 1 h. LacZ staining: LacZ expression 
was detected by incubating the tissue at 30 °C overnight in 0.1% X-gal, 5 mM 
potassium ferricyanide, 5 mM potassium ferrocyanide, 1 mM magnesium chloride 
0.002% NP-40, 0.01% sodium deoxycholate, PBS, pH 7.0 (ref. 58). Giemsa: Paraf-
fin sections were rehydrated and stained for several hours at 37 °C with standard 
Giemsa stain solution and subsequently rinsed in distilled water. The sections were 
differentiated with 0.5% aqueous acid acetic and rapidly dehydrated thereafter. For 
periodic acid Schiff staining: Paraffin sections were rehydrated, stained with peri-
odic acid 0.5% for 10 min, washed and stained again with Schiff reagent for 5 min. 
After dehydration and xylene clearing, slides were mounted and visualized.
Horseradish peroxidase staining and TUNEL analysis
For horseradish peroxidase staining. Endogenous peroxidase activity was inhibited 
by incubating sections for 15 min in 1% H2O2/methanol. Sections were then boiled 
in 10 mM citrate (pH 6) for 15 min for antigen retrieval, rinsed in Tris-HCl, pH 
7.6, and blocked with normal goat serum (1:10) for 5 min. Primary rat anti-mouse 
Ki67 (Dako M7249), rat anti-mouse F4/80 (Invitrogen MF48000) and S100 (Dako 
Z0311) antibodies were diluted 1:50, 1:20 and 1:1000, respectively, in Tris-HCl, 
pH 7.6, 0.5% BSA and applied to sections for 1 h at room temperature. Following 
rinsing, specific binding was revealed by incubating with horseradish peroxidase 
(HRP)-conjugated goat anti-rat polyclonal antibody (1:200) for 30 min and subse-
quent incubation with a 50-fold diluted HRP substrate (DAB; DAKO) for 7 min. 
Nuclei were counterstained using Harris haematoxylin. For TUNEL analysis: 
Following deparaffinization and rehydration, sections were pretreated with protein-
ase K (20 µg ml − 1 in PBS, 30 min) at room temperature. PBS-rinsed sections were 
preincubated in TdT reaction buffer (25 mM Tris-HCl, 200 mM sodium cacodylate, 
0.25 mg ml − 1 BSA, 1 mM cobalt chloride) for 10 min and incubated for 1–2 h at 
37 °C in a humidified chamber. The reaction was stopped by incubation with 
300 mM NaCl and 30 mM sodium citrate for 10 min, and detection was performed 
with streptavidin-HRP in PBS for 20 min. Nuclei were counterstained with Gill’s 
haematoxylin. Slides were dehydrated and covered with mounting medium. 
Positively stained cells were counted from three animals independently analysed 
per group. A minimum of three random pictures per section were taken using an 
Axion HRC (Carl Zeiss MicroImaging Inc.).
FACS analysis. Single cell suspensions were prepared from postnatal day-6 ventral 
skin31,32. After washing in PBS/5% FCS, the cells were stained for flow cytometry 
using standard procedures. The following monoclonal antibody conjugates were 
used to define cell subsets: CD45-Alexa 700 (30.H12), CD11c-APC (N4/18), 
CD3-PE (17A2), F4/80-APC-efluoro 780 and TCRVg3-FITC (536). All were 
purchased from eBioscience, except TCR Vg3-FITC, which was purchased from 
BD Pharmingen. DAPI (Invitrogen) was used for dead cell discrimination. Samples 
were analysed on an LSR II Flow Cytometer (Becton Dickinson) equipped with 
488, 407 and 640 lasers and data analysed with FlowJo software (TreeStar).
Electron microscopy. Skin biopsy samples were minced to  < 0.5 mm3, fixed in 
modified Karnovsky’s fixative overnight and postfixed in either 0.2% ruthenium 
tetroxide or 1% aqueous osmium tetroxide, containing 1.5% potassium ferro-
cyanide. After fixation, samples were dehydrated in a graded ethanol series, and 
embedded in an Epon–epoxy mixture. After selection of sites with perpendicu-
lar cross-sectioning in 1 mm toluidine blue-stained, epoxy-embedded sections, 
ultrathin sections were examined, with or without further contrasting with lead 
citrate, using a Zeiss 10A electron microscope (Carl Zeiss), operated at 60 kV.
Measurement of TEWL. The rate of TEWL from the ventral skin of preshaved, 
2-week-old, anaesthetized transgenic and littermate controls was measured using  
a Tewameter TM210 (Courage and Khazaka)8. The mean ± s.e.m. is shown.
Western blot analysis. Skin was homogenized using Tissue Lyzer (Qiagen) in 
8 M urea, EDTA 10 mM, Tris-HCl 50 mM, pH 8. Following 30 min incubation 
on ice, lysates were centrifuged (13,000 g for 15 min at 4 °C) and quantified using 
the Pierce BCA protein assay (Thermo Fisher Scientific). For SDS-PAGE, 50 µg 
proteins was loaded and separated on a 4–16% acrylamide gradient gel. Western 
blot analysis was performed using rabbit anti-mouse antibodies to K14 (1:10,000), 
K1, K6, filaggrin, loricrin and involucrin (1:1,000, Covance). Signals were revealed 
using anti-rabbit immunoglobulin G from donkey (1:2,000) as secondary antibody 
and the Pierce Fast Western Blot Kit SuperSignal West Dura (Thermo Fisher  
Scientific) detection system.
Tight junction functional assay. Junctional integrity of the epidermis was addressed 
by assessing diffusion of intradermally injected NHS-LC biotin8. Staining was visual-
ized using an LSM confocal microscope after incubation of sections with AlexaFluor 
488-conjugated streptavidin (Invitrogen) overnight at 4 °C. Nuclei were counterstained 
with 0.2 µg ml − 1 DAPI (Roche) in mounting media (Dako Schweiz AG).
Semiquantitative and quantitative RT–PCR. Skin was homogenized using Tissue 
Lyzer (Qiagen) and RNA was extracted with the Qiagen RNeasy Mini kit following 
the manufacturer’s instructions. A volume of 1.5 µg of RNA was treated with RQ1 
RNase-free DNase and reverse transcribed using M-MLV Reverse Transcriptase 
RNase H Minus Point Mutant (Promega). Real-time PCR was performed by  
TaqMan PCR using Applied Biosystems 7500. Each measurement was taken in 
triplicate. Quantification of fluorescence was normalized to β-actin. Amplified 
PCR products were separated on 2% agarose gel and visualized by ethidium  
bromide staining. Primer sequences are shown in Supplementary Table S2.
Lipid analyses. Whole skin from newborns was removed at autopsy, frozen and 
stored at  − 20 °C until further treatment. Stratum corneum lipids were homo-
genized, lyophilized and weighted. Epidermal lipids were extracted for 24 h at  
37 °C in solvent mixtures (chloroform/methanol/water)59.
Statistical analysis. All data are expressed as means ± s.e.m. Individual groups 
were compared using the Wilcoxon Mann–Whitney test, except for lipid analyses 
for which the Welch Two Sample Student’s t-test was applied. A level of P < 0.05  
was considered statistically significant for all comparisons; *P < 0.05, **P < 0.01  
and ***P < 0.001. 
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